Narrative review positing the gut-brain axis as a mechanistic link between type 2 diabetes and Parkinson's disease, highlighting microbial dysbiosis, metabolic inflammation, insulin/GLP-1 signaling, and potential alpha-synuclein propagation pathways.

Suggests actionable translational avenues—microbiome-targeted therapies and repurposing diabetes drugs (e.g., GLP-1 agonists)—that could influence PD progression, but the lack of an abstract and primary data limits immediate therapeutic impact and prioritization.